AcquisitionsJun 8, 2026, 08:31 AM
Galmed Pharmaceuticals to Acquire Colospan Ltd. for $4.5M
AI Summary
Galmed Pharmaceuticals Ltd. announced its intention to acquire Colospan Ltd. for a total consideration of $4.5 million, comprising $2.5 million in cash and $2 million in Galmed's ordinary shares. The acquisition, expected to close in the second quarter of 2026, aims to integrate Colospan's medical device development for the digestive system. Colospan's financial statements as of December 31, 2025, reveal $1.25 million in assets and $4.32 million in liabilities, with a net loss of $316,000 for the year. The auditor's report highlights substantial doubt about Colospan's ability to continue as a going concern due to recurring losses and a shareholders' deficit.
Key Highlights
- Galmed Pharmaceuticals Ltd. to acquire Colospan Ltd. for $2.5M cash and $2M in stock.
- Acquisition expected to close in Q2 2026.
- Colospan reported $1.25M in assets and $4.32M in liabilities as of Dec 31, 2025.
- Colospan reported a net loss of $316K for the year ended Dec 31, 2025.
- Colospan has recurring losses from operations and a shareholders' deficit, raising going concern doubts.
- Galmed will issue pre-funded warrants for shares exceeding 4.99% ownership.
- 7.5% of cash and stock consideration will be held in escrow for 12 months.
Price Impact
More from GLMD